東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Genetic strategies for improvement o...

Ward, Toby Michael.

FindBook

Google Book

Amazon

博客來

Genetic strategies for improvement of varicella vaccines.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Genetic strategies for improvement of varicella vaccines./
作者:	Ward, Toby Michael.
面頁冊數:	170 p.
附註:	Adviser: Wayne L. Gray.
Contained By:	Dissertation Abstracts International68-11B.
標題:	Biology, Microbiology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3289553
ISBN:	9780549327615

Genetic strategies for improvement of varicella vaccines.
Ward, Toby Michael.

Genetic strategies for improvement of varicella vaccines. - 170 p.

Adviser: Wayne L. Gray.

Thesis (Ph.D.)--University of Arkansas for Medical Sciences, 2008.

The live attenuated Oka vaccine is safe and effective for the prevention of primary disease caused by varicella zoster virus (VZV), which causes chickenpox (varicella) and shingles (herpes zoster) in humans. However, several problems concerning the vaccine still exist. The molecular basis of attenuation is unknown, vaccine lots are polygenic, and the vaccine is able to reactivate in humans to cause shingles. Evaluation of candidate second-generation VZV vaccines is hindered by the lack of an appropriate animal model in which to study pathogenesis, immunogenicity, and reactivation of engineered viruses. Simian varicella virus (SVV) is a closely related alphaherpesvirus of nonhuman primates, causing varicella- and zoster-like diseases in animals and offering a model system in which to evaluate potential vaccine strains.

ISBN: 9780549327615Subjects--Topical Terms:

1017734
Biology, Microbiology.

Genetic strategies for improvement of varicella vaccines.
LDR:03559nam 2200313 a 45 001 958788
005 20110704
008 110704s2008 ||||||||||||||||| ||eng d
020 $a 9780549327615
035 $a (UMI)AAI3289553
035 $a AAI3289553
040 $a UMI $c UMI
100 1 $a Ward, Toby Michael. $3 1282245
245 1 0 $a Genetic strategies for improvement of varicella vaccines.
300 $a 170 p.
500 $a Adviser: Wayne L. Gray.
500 $a Source: Dissertation Abstracts International, Volume: 68-11, Section: B, page: 7105.
502 $a Thesis (Ph.D.)--University of Arkansas for Medical Sciences, 2008.
520 $a The live attenuated Oka vaccine is safe and effective for the prevention of primary disease caused by varicella zoster virus (VZV), which causes chickenpox (varicella) and shingles (herpes zoster) in humans. However, several problems concerning the vaccine still exist. The molecular basis of attenuation is unknown, vaccine lots are polygenic, and the vaccine is able to reactivate in humans to cause shingles. Evaluation of candidate second-generation VZV vaccines is hindered by the lack of an appropriate animal model in which to study pathogenesis, immunogenicity, and reactivation of engineered viruses. Simian varicella virus (SVV) is a closely related alphaherpesvirus of nonhuman primates, causing varicella- and zoster-like diseases in animals and offering a model system in which to evaluate potential vaccine strains.
520 $a Using molecular cloning techniques, recombinant SVV (rSVV) viruses were engineered by deleting genes potentially involved in pathogenesis, latency and/or reactivation. Viral genes involved in DNA replication and nucleotide metabolism were targeted, specifically the deoxyUTPase (SVV gene 8), the UNG (SVV gene 59), and the ribonucleotide reductase (large subunit, SVV gene 19). Furthermore, viral regulatory genes including the transactivator gene 61 and the latency-associated transcript were targeted in attempts to attenuate the virus, particularly with regard to latency. PCR and RT-PCR analyses confirmed deletion of viral genes, and in vitro characterization of rSVVs confirmed their viability.
520 $a The Oka vaccine is an attractive vector for the delivery of antigens from unrelated pathogens, as a strategy to protect against other diseases. Respiratory syncytial virus (RSV) is the most important viral respiratory pathogen of infants, and is also a major pathogen of the elderly and immunocompromised; to date, no successful vaccine exists. rSVV viruses were engineered to express the G glycoprotein and M2 second matrix protein from RSV, in order to form bivalent vaccines. Immunofluorescence and western blot assays confirmed the expression of RSV antigens by rSVV vaccines, and viruses were viable in vitro. Rhesus macaque monkeys were immunized with rSVV-RSV recombinant viruses, and exhibited humoral immune responses to both the SVV vector and to the RSV trans-antigens.
520 $a The results of these genetic studies using SVV reveal several potential strategies toward improvement of varicella vaccines. Defined attenuation mutations, clonal vaccine strains, and bivalent vaccines are exciting avenues of research that may lead to the next generation of vaccination against VZV and other pathogens.
590 $a School code: 0365.
650 4 $a Biology, Microbiology. $3 1017734
650 4 $a Biology, Virology. $3 1019068
690 $a 0410
690 $a 0720
710 2 $a University of Arkansas for Medical Sciences. $3 1021816
773 0 $t Dissertation Abstracts International $g 68-11B.
790 $a 0365
790 1 0 $a Gray, Wayne L., $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3289553